Skye Bioscience (SKYE) 2025 Conference June 05, 2025 09:20 AM ET Speaker0 Morning, and welcome everyone to the Jefferies Global Healthcare Conference. I'm Jordan Carey with the investment banking team, and it's my pleasure to introduce Puneet Dillon, CEO of Sky Biosciences. Speaker1 Okay. Thank you so much. All right. Good morning, everyone. Yes, thank you again for the invitation and being here at Jefferies. It's always a pleasure seeing the entire Jefferies team and talking about what we're working on at ...

SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will participate in the following upcoming healthcare conferences: Investment Conferences Jefferies Global Healthcare Conference (New York)   Presentation Thursday, June 5, 9:20 AM ET + 1x1 meetings Sachs European BioPharma Obesity Innovation Forum   Next Gen Th ...

Core Insights - Skye Bioscience is collaborating with Arecor Therapeutics to develop a higher concentration formulation of nimacimab, a CB1 inhibitor, utilizing Arecor's Arestat™ technology [1][2][3] - Nimacimab is currently being evaluated in a Phase 2a clinical trial for obesity, with initial data expected in late Q3 or early Q4 2025 [2][5] - The partnership allows Skye to fund Arecor's development activities and potentially license the new formulation and associated intellectual property [2][3] Company Overview - Skye Bioscience focuses on developing next-generation therapeutic pathways for metabolic health, particularly through G-protein coupled receptors [5] - The company is conducting a Phase 2a clinical trial for nimacimab, which is a negative allosteric modulating antibody that inhibits CB1 [5] - Arecor Therapeutics aims to enhance existing therapeutic products and has a proprietary technology platform, Arestat™, supported by a strong patent portfolio [4] Product Development - Nimacimab has a pharmacokinetic profile with a half-life of 18–21 days, which is significantly longer than GLP-1-based therapies, and is being evaluated for once-weekly dosing [3] - The collaboration aims to address issues related to tolerability and adherence seen in approved weight loss drugs, as well as concerns about neuropsychiatric toxicities associated with small molecule CB1 inhibitors [3]

Skye Bioscience (SKYE) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Bernie Hertel - Head IR & CommunicationsPunit Dhillon - President, CEO, Secretary & DirectorChris Twitty - Chief Scientific OfficerKaitlyn Arsenault - Chief Financial OfficerPuneet Arora - Chief Medical Officer Conference Call Participants None - AnalystJay Olson - Managing Director & Senior Analyst - BiotechnologyAlbert Lowe - Senior Research AnalystEdward Tenthoff - Sr. Research AnalystKristen Kluska - AnalystAndy H ...

Skye Bioscience (SKYE) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Ladies and gentlemen, thank you for standing by. My name is JL, and I will be your conference operator today. At this time, I would like to welcome everyone to the Sky BioScience First Quarter Fiscal twenty twenty five Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. I would now like to turn the conference over to Bernie He ...

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity SAN DIEGO, CA, May 8, 2025 -- Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye" or the "Company"), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2025, along with key accomplishments and upcoming milestones. "In Q1, we ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _____________________________________________________________ (Exact name of registrant as specified in its charter) Nevada 45-0692882 (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Co ...

Nimacimab in combination with tirzepatide improves weight loss effect over tirzepatide alone, and shows comparable weight loss to monlunabant and tirzepatide alone in preclinical diet-induced obesity modelIn vitro data reported from new preclinical study highlights superior potency of peripherally restricted CB1 inhibitor, nimacimab, versus monlunabant when tested under pathological levels of CB1 agonistsExpanded preclinical study data to be presented at ADA in June 2025Top-line data readout from CBeyond™ P ...

Skye Bioscience (SKYE) 2025 Conference May 08, 2025 11:00 AM ET Speaker0 two of the Citizens Life Science Conference. My name is John Walden, senior analyst here. We're pleased to have Sky Bioscience and Puneet Dillon, CEO joining us to tell us a little bit about the story. Sky, we initiated coverage on just a little while ago, but, this is a name that I think is underappreciated in the obesity space going after, you know, a relatively novel well, not novel mechanism, but way less crowded space with some di ...

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, May 8th at 1:30 p.m. PT/4:30 p.m. ET to discuss its 2025 first quarter financial results. An earnings press release will be issued after the market close on May 8th. LifeSci Advisors, Mike Moyer mmoyer@lifesciadvisors.com (617) 308-4306 The live ...